levetiracetam
levetiracetam is listed in the FDA National Drug Code directory with 56 NDC codes, marketed under brand names including Levetiracetam, Spritam, levetiracetam. Available dosage forms: tablet, for suspension, tablet, film coated, injection, injection, solution, concentrate, tablet, film coated, extended release.
Drug details
- Generic Name
- levetiracetam
- Brand Names
- Levetiracetam, Spritam, levetiracetam, Keppra XR, Keppra, Levetiracetam Extended-Release, ELEPSIA XR 1000 MG, LEVETIRACETAM, ELEPSIA XR 1500 MG
- Application Number
- NDA207958
- Sponsor
- Prasco Laboratories
- NDC Codes
- 56
- Dosage Forms
- TABLET, FOR SUSPENSION, TABLET, FILM COATED, INJECTION, INJECTION, SOLUTION, CONCENTRATE, TABLET, FILM COATED, EXTENDED RELEASE, INJECTION, SOLUTION, POWDER, TABLET, EXTENDED RELEASE, SOLUTION
- Routes
- ORAL, INTRAVENOUS
- Active Ingredients
- LEVETIRACETAM
Indications and Usage
1 INDICATIONS AND USAGE Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: • Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2) • Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3) 1.1 Partial-Onset Seizures Levetiracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy Levetiracetam tablets are indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures Levetiracetam tablets are indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.